Literature DB >> 19064739

Stem cell concepts renew cancer research.

John E Dick1.   

Abstract

Although uncontrolled proliferation is a distinguishing property of a tumor as a whole, the individual cells that make up the tumor exhibit considerable variation in many properties, including morphology, proliferation kinetics, and the ability to initiate tumor growth in transplant assays. Understanding the molecular and cellular basis of this heterogeneity has important implications in the design of therapeutic strategies. The mechanistic basis of tumor heterogeneity has been uncertain; however, there is now strong evidence that cancer is a cellular hierarchy with cancer stem cells at the apex. This review provides a historical overview of the influence of hematology on the development of stem cell concepts and their linkage to cancer.

Entities:  

Mesh:

Year:  2008        PMID: 19064739     DOI: 10.1182/blood-2008-08-077941

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  400 in total

1.  The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Authors:  Benjamin Mizukawa; Eric O'Brien; Daniel C Moreira; Mark Wunderlich; Cindy L Hochstetler; Xin Duan; Wei Liu; Emily Orr; H Leighton Grimes; James C Mulloy; Yi Zheng
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

Review 2.  Cancer stem cells: a stride towards cancer cure?

Authors:  Amitava Sengupta; Jose A Cancelas
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

3.  Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain.

Authors:  Andre Larochelle; Jennifer M Gillette; Ronan Desmond; Brian Ichwan; Amy Cantilena; Alexandra Cerf; A John Barrett; Alan S Wayne; Jennifer Lippincott-Schwartz; Cynthia E Dunbar
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

4.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Authors:  Marcus Järås; Petra Johnels; Nils Hansen; Helena Agerstam; Panagiotis Tsapogas; Marianne Rissler; Carin Lassen; Tor Olofsson; Ole Weis Bjerrum; Johan Richter; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

5.  Evidence that growth factor independence 1b regulates dormancy and peripheral blood mobilization of hematopoietic stem cells.

Authors:  Cyrus Khandanpour; Ehssan Sharif-Askari; Lothar Vassen; Marie-Claude Gaudreau; Jinfang Zhu; William E Paul; Taro Okayama; Christian Kosan; Tarik Möröy
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

6.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Authors:  Hongwu Zheng; Haoqiang Ying; Ruprecht Wiedemeyer; Haiyan Yan; Steven N Quayle; Elena V Ivanova; Ji-Hye Paik; Hailei Zhang; Yonghong Xiao; Samuel R Perry; Jian Hu; Anant Vinjamoori; Boyi Gan; Ergun Sahin; Milan G Chheda; Cameron Brennan; Y Alan Wang; William C Hahn; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 7.  Targeting leukemic stem cells by breaking their dormancy.

Authors:  Marieke Alida Gertruda Essers; Andreas Trumpp
Journal:  Mol Oncol       Date:  2010-06-09       Impact factor: 6.603

Review 8.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

Review 9.  CD133-targeted niche-dependent therapy in cancer: a multipronged approach.

Authors:  Anthony B Mak; Caroline Schnegg; Chiou-Yan Lai; Subrata Ghosh; Moon Hee Yang; Jason Moffat; Mei-Yu Hsu
Journal:  Am J Pathol       Date:  2014-02-28       Impact factor: 4.307

Review 10.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.